title: Role of C3 cleavage in monocyte activation during extracorporeal circulation.
abstract: BACKGROUND
  We previously demonstrated that inhibiting formation of terminal complement components (C5a and C5b-9) prevents platelet and neutrophil (PMN) but not monocyte activation during simulated extracorporeal circulation (SECC). This study examined whether earlier complement inhibition during SECC, blocking C3a formation, would additionally prevent monocyte activation.
  
  
  RESULTS
  SECC was established by recirculating heparinized whole blood from human volunteers on a membrane oxygenator. CAB-2, a chimeric protein constructed from genes encoding the complement regulatory proteins CD46 and CD55, inactivates the C3/C5 convertases and blocks in vitro generation of C3a, C5a, and C5b-9. CAB-2 was used in 4 experiments at a final concentration of 300 micrograms/mL and 4 experiments at 30 micrograms/mL; 4 control runs used vehicle alone. Samples were assayed for C3a and C5b-9, monocyte activation (CD11b upregulation), PMN activation (CD11b upregulation and elastase release), and platelet activation (P-selectin expression and monocyte-platelet conjugate formation). CAB-2 at both doses significantly inhibited formation of C3a and C5b-9 during SECC. High-dose CAB-2 significantly blocked monocyte and PMN CD11b upregulation and PMN elastase release. CAB-2 also inhibited formation of platelet activation-dependent monocyte-platelet conjugates.
  
  
  CONCLUSIONS
  Blockade of complement activation early in the common pathway inhibited monocyte CD11b upregulation during SECC, suggesting that early complement components contribute most to monocyte activation during SECC. As expected, PMN and platelet activation were blocked by terminal complement inhibition. This investigation further elucidates the relation between complement and blood cell activation during simulated cardiopulmonary bypass.
authors.affiliation: Department of Laboratory Medicine and Anesthesiology, Yale University School of Medicine, New Haven, CT 06520-8035, USA. christine.rinder@yale.edu
authors.forename: C S
authors.initials: CS
authors.lastname: Rinder
authors.forename: H M
authors.initials: HM
authors.lastname: Rinder
authors.forename: K
authors.initials: K
authors.lastname: Johnson
authors.forename: M
authors.initials: M
authors.lastname: Smith
authors.forename: D L
authors.initials: DL
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Tracey
authors.forename: G
authors.initials: G
authors.lastname: Polack
authors.forename: P
authors.initials: P
authors.lastname: Higgins
authors.forename: C G
authors.initials: CG
authors.lastname: Yeh
authors.forename: B R
authors.initials: BR
authors.lastname: Smith
mesh_terms: D001792:Blood Platelets / Q000378:metabolism; D018845:CD11 Antigens / Q000187:drug effects / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects; D015926:Complement C3a / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D015936:Complement C5a / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D005112:Extracorporeal Circulation; D006801:Humans; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D009504:Neutrophils / Q000378:metabolism; D015539:Platelet Activation / Q000187:drug effects; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D018845:CD11 Antigens; D011993:Recombinant Fusion Proteins; D015926:Complement C3a; D015936:Complement C5a